STOCK TITAN

Ensysce Biosciences, Inc. - ENSC STOCK NEWS

Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.

Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a San Diego-based clinical-stage biotech company specializing in the development of safer prescription drugs using its proprietary technology platforms. The company focuses on creating new, tamper-proof opioids that aim to reduce drug abuse and prevent overdoses. Ensysce leverages its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms to develop innovative pain relief options with a lower risk of misuse.

The company’s core projects include two key drug platforms: the TAAP technology, which activates upon ingestion to release pain medication, and the MPAR technology, designed to prevent overdose by inhibiting further release of the drug when excess doses are consumed. These platforms are supported by global intellectual property protection, ensuring a wide array of prescription drug compositions.

Recent milestones include the FDA’s Breakthrough Therapy designation for PF614-MPAR, a combination product designed to provide overdose protection alongside effective pain relief. This designation accelerates the drug’s development and review process, highlighting its potential to offer substantial improvements over existing therapies. Ensysce’s lead candidate, PF614, is currently in Phase 3 clinical development, having demonstrated efficacy and safety in previous trials.

In terms of financial health, Ensysce has shown stability, with recent funding from federal grants and warrant exercises supporting ongoing research and development. The company's collaboration with Quotient Sciences aims to further optimize their PF614-MPAR drug product, enhancing its effectiveness and safety profile.

Ensysce is also expanding its product pipeline to address opioid use disorder (OUD) with PF9001, a TAAP-based candidate that has shown promise in reducing cardiovascular side effects compared to traditional treatments. Supported by a multi-year HEAL grant from the NIH and NIDA, this candidate is poised to enter human clinical studies within the next 12 to 18 months.

For more detailed information about Ensysce Biosciences, Inc. and its innovative projects, please visit www.ensysce.com.

Rhea-AI Summary

Ensysce Biosciences (NASDAQ: ENSC) has achieved a critical milestone in its opioid use disorder (OUD) program. The company has selected PF9001, a lead drug candidate designed to reduce abuse potential and improve safety, particularly with lower cardiovascular risks compared to traditional treatments. The candidate will proceed to Investigational New Drug (IND) enabling studies, backed by a $15 million NIH and NIDA HEAL award. CEO Dr. Lynn Kirkpatrick highlighted the adaptability of Ensysce's TAAP technology in producing controlled-activation drug candidates. Human clinical studies are expected to begin within 12 to 18 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
Rhea-AI Summary

Ensysce Biosciences announced that its Chief Commercial Officer, Geoff Birkett, will participate in the EPHMRA 2024 Annual Conference in London from June 24-27, 2024. Birkett will be part of the opening panel discussion on June 25, titled 'The Future of Healthcare Market Research,' and will lead a presentation on June 26 about customer engagement strategy development. Birkett, known for his expertise in market research and commercialization, is pivotal in preparing for the launch of Ensysce's lead product, PF614, and the innovative follow-on drug, PF614-MPAR, an opioid with oral overdose protection. His insights have been essential in advancing Ensysce's portfolio aimed at severe pain relief while mitigating opioid misuse and overdose.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
-
Rhea-AI Summary

Ensysce Biosciences has regained compliance with Nasdaq's Listing Rule 5550(b)(1), according to a notice received on May 24, 2024.

The compliance relates to the equity requirement as per the Hearing Panel's decision dated February 26, 2024. As a result, Ensysce's common stock will continue to trade on Nasdaq's Capital Market tier.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
Rhea-AI Summary

Ensysce Biosciences has renewed its collaboration with Quotient Sciences to advance the clinical development of its overdose protection platform, PF614-MPAR. This innovative opioid product, designed to prevent overdose by shutting off opioid release when too many pills are ingested, is undergoing a Phase 1b study to evaluate its efficacy and safety across different doses. The study, PF614-MPAR-102, will assess doses of 25 mg, 50 mg, and 100 mg administered twice daily for five days. PF614-MPAR, which has received Breakthrough Therapy designation from the FDA, aims to provide a safer solution for severe pain management and address the ongoing opioid overdose crisis in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.43%
Tags
-
Rhea-AI Summary

Ensysce Biosciences reported their first quarter 2024 financial results, highlighting progress in their clinical programs with FDA breakthrough therapy designations for their lead opioid products, PF614 and PF614-MPAR. The company received positive feedback and guidance from the FDA, affirming their path to regulatory approval and commercialization. Ensysce is set to begin Phase 3 clinical trials in the second half of 2024, showcasing their innovative TAAP and MPAR opioids for severe pain relief with reduced abuse potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.64%
Tags
-
Rhea-AI Summary
Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick featured in Xtalks Clinical Edge Magazine discussing the Company's innovative solutions for pain relief and opioid abuse reduction. Dr. Kirkpatrick highlights Ensysce's Breakthrough Therapy designation by the FDA for PF614-MPAR technology and her journey in medicinal chemistry and drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
Rhea-AI Summary
Ensysce Biosciences, a clinical stage pharmaceutical company (NASDAQ: ENSC), presented at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. The webcast discussed the Company's innovative solutions for pain relief with reduced opioid abuse risk. CEO Dr. Lynn Kirkpatrick highlighted TAAP and MPAR technology, lead drug candidates PF614 and PF614-MPAR, FDA Breakthrough Therapy designation for PF614-MPAR, and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
-
Rhea-AI Summary
Ensysce Biosciences, Inc. (ENSC) announces participation in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. The company focuses on developing innovative solutions for severe pain relief while reducing opioid misuse. Dr. Lynn Kirkpatrick and Dave Humphrey will present at the conference, offering a Q&A session. Attendees can register for the event for free and access the webcast later. Ensysce's management team will also be available for one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Ensysce Biosciences, Inc. reports financial results for Q4 and full year 2023, discusses FDA Breakthrough Therapy Designation, Phase 3 plans, and updates on TAAP and MPAR programs. The Company's CEO highlights progress in clinical studies and regulatory approvals, emphasizing the potential of their innovative opioid products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) receives extension from Nasdaq to demonstrate compliance with equity requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none

FAQ

What is the current stock price of Ensysce Biosciences (ENSC)?

The current stock price of Ensysce Biosciences (ENSC) is $8.1 as of December 20, 2024.

What is the market cap of Ensysce Biosciences (ENSC)?

The market cap of Ensysce Biosciences (ENSC) is approximately 9.8M.

What is Ensysce Biosciences, Inc.?

Ensysce Biosciences, Inc. is a clinical-stage biotech company in San Diego focused on developing safer prescription drugs using proprietary abuse deterrent and overdose protection technologies.

What technologies does Ensysce use in its drug development?

Ensysce employs its proprietary Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) technologies to create tamper-proof drugs that minimize the risk of abuse and overdose.

What are the core products in Ensysce’s development pipeline?

The core products include PF614, an extended-release oxycodone utilizing TAAP technology, and PF614-MPAR, which combines overdose protection with effective pain relief.

What recent achievements have Ensysce made?

Ensysce has received Breakthrough Therapy designation from the FDA for PF614-MPAR, highlighting the product's potential to improve pain management while preventing overdoses.

What is the significance of FDA Breakthrough Therapy designation?

The Breakthrough Therapy designation expedites the development and review process for drugs that show substantial improvement over existing therapies, facilitating faster access to patients.

How is Ensysce addressing the opioid epidemic?

Ensysce is developing tamper-proof opioids that reduce the risk of abuse and overdose, with products like PF614-MPAR designed to prevent the release of excess doses and provide safer pain management options.

What financial strategies support Ensysce’s operations?

Ensysce’s financial health is bolstered by federal grants and warrant exercises, which help fund its ongoing research and development efforts.

What partnerships has Ensysce formed to advance its drug development?

Ensysce collaborates with Quotient Sciences to optimize and test its drug products, enhancing their safety and effectiveness through innovative translational pharmaceutics processes.

What future projects is Ensysce Biosciences involved in?

Ensysce is expanding its pipeline to include PF9001 for opioid use disorder (OUD), supported by significant funding from the NIH and NIDA to move into human clinical studies.

Where can more information about Ensysce Biosciences be found?

Additional details about Ensysce Biosciences can be found on their official website at www.ensysce.com.

Ensysce Biosciences, Inc.

Nasdaq:ENSC

ENSC Rankings

ENSC Stock Data

9.79M
895.96k
1.17%
22.26%
42.61%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA